Don't Fly and Freeze: Impact of Ex-Vivo-Time, Cell Concentration and Cryopreservation on the Composition of Allogeneic Stem Cell Grafts

Background CD34+ cells are considered the active substance in allogenic hematopoietic stem cell (aHSC) grafts. However, immunologically active cellular “contaminants” make up >90% of nucleated cells in aHSC grafts, and are crucial for treatment success in hematological disorders. Following COVID-19 pandemic restrictions that were implemented due to supply chain interruptions and infection risk concerns, we conducted a prospective quality analysis on cell composition and viability before and after cryopreservation in aHSC grafts. Methods We analyzed fresh grafts from matched related (n=192) and unrelated (MUD; n=263) donors, and cryopreserved grafts (related, n=34; unrelated, n=97) between April 2020 and December 2023; cell composition, concentration, and time spent ex-vivo (apheresis to infusion/cryopreservation) were recorded. Flow cytometric analysis was carried out upon receipt at our institution and after thaw (if cryopreserved). Viability and absolute counts were studied in CD34+ stem cells, monocytes (CD14+), T cells (CD3+, CD4+ and CD8+), B cells (CD19+), and NK cells (CD56+). Grafts were received from 22 countries (grouped into 3 regions: Asia, Europe, Americas); many were also obtained through local apheresis (all related donors). Results Upon arrival, CD34+ cell viability was 99.0% (82-100%), with the bottom 10% of MUD grafts showing low average viability of 88.1%. Overall CD3+ cells exhibited high viability of 98.3% (59.1-100), with MUD grafts largely contributing to the lowest values; 29 had CD3+ viability <93.7%. Viability of CD4+ cells ranged much wider than CD8+ cells (54.4-100% and 68.3-100%, respectively). Given these results, we analyzed the impact of ex-vivo time on viability. Locally acquired grafts (n=225) had short ex-vivo times (15.5h±11.0) compared to grafts from abroad (Asia, n=5, 59.7h±20.9; Europe, n=270, 44.2h±11.1; Americas, n=84, 27.0h±11.1). The effect of ex-vivo time on viability was significant for a cell types (p<0.001). As expected, there was a limited inverse correlation in CD34+ cells (R2=0.038). However, a strong inverse correlation was found in T cells (CD3+ cells R2=0.167, CD4+ R2=0.168, CD8+ R2=0.148, TCRα/β R2=0.172, TCRg/d, R2=0.044). The effect on viability was minimal in CD56+, 14+, and 19+ cells (all >99.5%, 92-100). Subsequently, we reasoned that cell concentration in the apheresis bag may equally impact viability. While CD34+ viability (R2=0.002, p=0.969) showed no correlation, CD45+ viability was significantly positively affected (R2=0.013, p=0.004). No correlation of viability with cell concentration was seen in CD14+ cells (R2=0.001, p=0.672), CD19+ cells (R2=0.002, p=0.755) and CD56+ cells (R2=0.000, p=0.293), but nearly all T cell subsets were positively affected (CD3+ R2=0.020, CD4+ R2=0.020, CD8+ R2=0.021, TCRα/β R2=0.021, all p<0.001, TCRg/d R2=0.002, p=0.159). Cell concentrations were higher in local products compared to MUD (p<0.001), prompting us to create an index to elucidate the relationship of both factors (PMIndex=Ex-Vivo time x cell concentration). PMindex was significantly inversely correlated with viability of all cell subsets (p<0.001), except CD19+ cells (p=0.409). Viability correlation was weak for CD34+ (R2=0.047), CD14+ (R2=0.121), and CD56+ (R2=0.069) cells. Viability was most affected in T cells when ex-vivo time was long and cell concentration was high: CD3+ R2=0.125, CD4+ R2=0.127, CD8+ R2=0.107, TCRα/β R2=0.129, TCRg/d R2=0.037 (all p<0.001). When grafts were analyzed post cryopreservation (n=131), high PMIndex did not impact CD34+ (p=0.944), CD14+ (p=0.148), CD19+ (p=0.054), and CD56+ (p=0.064) cells, while T cells were impacted substantially (p<0.001 for CD3+, 4+, 8+, and TCRα/β; TCRg/d p=0.121). Thus, cryopreservation significantly reduced the number of viable T cells infused (CD3+=-47.6%, CD4+=-52.1%, CD8+=-38.6%, TCRα/β=-48.0%, TCRg/d=-35.6%). CD34+ (-8.3%), CD14+ (-27.1%), CD19+ (-16.7%) and CD56+ (-21.3%) cells were only mildly affected. Conclusion All aHSC graft constituents are affected by ex-vivo time, cell concentration and cryopreservation; CD34+ cells are the most tolerant and T cells the most affected. The data presented may have clinical implications for patients receiving cryopreserved grafts with long ex-vivo times and high cell concentrations. More granular analysis of graft composition should be performed when cryopreservation is planned.

Récupéré en direct depuis OpenAlex et désinversé. Les résumés ne sont pas conservés dans cette base de données : les index inversés représentent 8,6 Go des 9,3 Go de texte de la base, et le serveur dispose de 13 Go libres.